An observational study on monoclonal antibodies against CGRP and its receptor.

Source: Eur J Neurol 2023 Mar 01; . doi: 10.1111/ene.15761Authors: Schiano di Cola F, Bolchini M, Ceccardi G, Caratozzolo S, Liberini P, Rao R, Padovani A

Based on their pharmacological target, two classes of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) have been identified: antibodies against the CGRP ligand – Galcanezumab, Fremanezumab, Eptinezumab – and the CGRP receptor (CGRP-R), Erenumab. Aim of the present study was to compare anti-CGRP versus anti-CGRP-R mAbs in patients with high frequency episodic and chronic migraine.

Pubmed ID: https://pubmed.ncbi.nlm.nih.gov/36856538/